[Skip to Content]
[Skip to Content Landing]
July 1, 1998

Cost-effectiveness of Zidovudine to Prevent Mother-to-Child Transmission of HIV in Sub-Saharan Africa

Author Affiliations

Margaret A.WinkerMD, Senior EditorIndividualAuthorPhil B.FontanarosaMD, Senior EditorIndividualAuthor

JAMA. 1998;280(1):30-31. doi:10-1001/pubs.JAMA-ISSN-0098-7484-280-1-jbk0701

To the Editor.— The Thai Ministry of Health and the US Centers for Disease Control and Prevention recently released preliminary results from their trial demonstrating a 51% reduction of mother-to-child transmission associated with short-course zidovudine given from 36 weeks' gestation through labor.1 Using this zidovudine efficacy estimate adjusted for a breast-feeding population, updated information on a range of counseling and testing costs,2,3 prenatal maternal testing rates (Bernard Nahlen, MD, oral communication, April 1998), and reductions in zidovudine cost (announced by Glaxo Wellcome, Inc4), we reevaluated our analysis3 of the cost-effectiveness of short-course zidovudine for prevention of mother-to-child human immunodeficiency virus (HIV) transmission for sub-Saharan African countries with the greatest burden of HIV in childbearing women and infants (eg, Ivory Coast, Tanzania, Uganda).

First Page Preview View Large
First page PDF preview
First page PDF preview